Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01228344 · ClinicalTrials.gov registry record
Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 324
- Enrollment target
NCT01228344 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 324 participants.
The verdict
NCT01228344 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 324 participants
- Enrollment target
Study Summary
The purpose of this study is to describe the pediatric and adult patients (U.S. and foreign residents) diagnosed with malaria and treated with artemether-lumefantrine with regard to their demographics, including evaluation of their malaria immune status, treatment effectiveness, prior and concomitant medication use, and the occurrence of adverse events in association with artemether-lumefantrine treatment, based on the information collected in the CDC Malaria Case Surveillance Report Form.
Interventions
- OTHER Artemether-lumefantrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2010-05-01 |
| Est. Completion | 2015-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01228344
The ClinicalTrials.gov registry entry for NCT01228344 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Artemether-lumefantrine is the first listed.
NCT01228344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01228344 about?
NCT01228344 is a clinical study titled "Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria". The purpose of this study is to describe the pediatric and adult patients (U.S. and foreign residents) diagnosed with malaria and treated with artemether-lumefantrine with regard to their demographics, including evaluation of their malaria immune status, treatment effectiveness, prior and concomitan...
What is the current status of trial NCT01228344?
This trial is currently completed. The enrollment target is 324 participants. The study started on 2010-05-01. Estimated completion is 2015-09-30.
What interventions are being tested in trial NCT01228344?
The interventions under investigation include: Artemether-lumefantrine (OTHER).
Who is sponsoring clinical trial NCT01228344?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.